Combining best-in-class electronic Clinical Outcome Assessment (eCOA) technology with expert rater training to reduce variability and strengthen clinical outcomes data in Central Nervous System (CNS) and other complex disorder clinical trials.
Meylan, France and Maidenhead, UK – April 15, 2026 – Kayentis, a global leader in electronic Clinical Outcome Assessment (eCOA), and RWS, a global AI solutions company, today announce a partnership combining RWS’ rater training service with Kayentis’ robust eCOA platform. This coordinated approach reduces variability in clinician assessments, enabling improved quality and reliability of Clinician-Reported Outcomes (ClinRO) in clinical trials, notably in Central Nervous System (CNS) studies that are complex.
Long study durations, intricate assessment scales and particularly vulnerable patient populations in CNS trials increase the risk of inconsistent data.
This collaboration focuses on one of the biggest challenges in neuroscience research: variability in clinician assessments, where even small inconsistencies in scoring or scale administration can affect endpoint reliability and, ultimately, the validity of trial results.
By combining Kayentis’ flexible eCOA platform with RWS’s specialist rater training, the partnership aims at helping sponsors and contract research organizations (CROs) reduce variability at both the human and technology levels.
Guillaume Juge
CEO at Kayentis
“Capturing data digitally isn’t enough, sponsors need data they can trust. By aligning rater qualification with purpose-built eCOA workflows, we help reduce variability and give teams greater confidence in their results. This partnership with RWS brings a more coordinated approach, aligning how clinicians are trained, certified and monitored with how data is captured and controlled.”
Clinical assessment improvements
The joint solution integrates training, certification and data capture into a single, quality-driven workflow across the full trial lifecycle. It includes:
- Specialist rater training, including qualification, certification and ongoing monitoring tailored to specific indications and assessment scales
- Advanced eCOA technology, designed for complex ClinRO administration and adaptable to real-world site conditions
- Integrated access controls, ensuring only certified clinicians can complete specific assessments, reducing the risk of unqualified or out-of-date raters
Together, these capabilities help improve consistency across sites, strengthen endpoint reliability and support inspection-ready datasets.
Designed for complex, global trials
The partnership offers a more streamlined model for sponsors and CROs managing complex studies. By aligning workflows and simplifying vendor management, it reduces operational burden while maintaining high standards of data quality.
Dan Herron
Global Vice President, Digital Health at RWS.
“Our CNS rater training service was built to tackle one of the biggest risks in neuroscience trials: inconsistent clinician assessments. Working with Kayentis allows us to connect that expertise directly to how data is captured in real-world trial environments.”
The partnership formalizes a long-standing collaboration between the two organizations and reflects recent investment on both sides. RWS has expanded its CNS offering with dedicated rater training services, while Kayentis has enhanced its Clin’form platform and strengthened its scientific advisory board with neuroscience expertise.
The joint solution is available immediately for sponsors and CROs running CNS and other complex trials requiring high-quality ClinRO data from study start through closeout.
About Kayentis
Kayentis is a global leader in electronic Clinical Outcome Assessment (eCOA) and Decentralized Clinical Trial solutions. For over 20 years, it has partnered with pharma, biotechs and CROs in streamlining data collection and enhancing data quality across clinical trials worldwide. To date, Kayentis has supported more than 400 clinical trials across 30,000 sites in over 90 countries. Its expertise spans all clinical phases (I–IV) and more than 200 indications across 20+ therapeutic areas, delivering a comprehensive, science-driven and patient-centric suite of services. Operating across the US, Europe and Asia, Kayentis is recognized for its commitment to quality, innovation and operational excellence. With a 95.9% client recommendation rate in 2026, consistently rating above 90% over the past five years, Kayentis continuously adapts its solutions to meet the growing complexity of clinical trials and to improve outcomes for sponsors, sites and patients alike.
About RWS
RWS is a global AI solutions company empowering the world’s most trusted enterprise AI. Our proprietary Cultural Intelligence Layer, powered by 250,000 data specialists, cultural and language experts and deep domain professionals, backed by 45+ patents, makes enterprise AI culturally fluent, contextually accurate and secure, ensuring every interaction reflects a brand’s tone, context and customer values. Through our Generate, Transform and Protect segments, we deliver intelligent content, enterprise knowledge, large-scale localization and IP protection for global growth. Trusted by 80+ of the world’s top 100 brands, RWS provides the confidence, governance and expertise organizations need to deploy AI safely, responsibly and at scale. Headquartered in the UK, RWS is listed on AIM (RWS.L).
Media & analyst contact
Andrew Lloyd & Associates
Carol Leslie / Juliette Schmitt
carol@ala.associates / juliette@ala.associates
UK: +44 1273 952 481
US: +1 203 724 5950
